Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evommune, Inc.EVMN · Entity 5539 | Chief of Dev. Operations | June 22, 2026 | June 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evommune, Inc.
Report date June 22, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,794 |
Ending reported balance
After 2026-06-22 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-06-22 · Exercise / conversion · Acquired 3,839 · Balance 71,633 F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026. Row 2 · 2026-06-22 · Exercise / conversion · Acquired 16,161 · Balance 87,794 F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026. Row 3 · 2026-06-22 · Sale · Disposed 20,000 · Balance 67,794 F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026. F2: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.84 · Expires 2033-05-11 | Direct | 53,795 |
Reported balance
After 2026-06-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-22 · Exercise / conversion · Disposed 3,839 · Balance 53,795 F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026. F3: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.99 · Expires 2034-12-08 | Direct | 39,321 |
Reported balance
After 2026-06-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-22 · Exercise / conversion · Disposed 16,161 · Balance 39,321 F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026. F3: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026.
F2: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F3: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2026 Filed Jun 25, 2026 00:00 UTC | Evommune, Inc. EVMN · Entity 5539 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 16,161 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0002091053-26-000005 · primarydocument.xml · derivative · entry 5 Drew Janice Suzann · CIK 0002091053 · Chief of Dev. Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,321 Underlying: Common Stock · 16,161 shares Expires 2034-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026. F3 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 22, 2026 Filed Jun 25, 2026 00:00 UTC | Evommune, Inc. EVMN · Entity 5539 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,839 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0002091053-26-000005 · primarydocument.xml · derivative · entry 4 Drew Janice Suzann · CIK 0002091053 · Chief of Dev. Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,795 Underlying: Common Stock · 3,839 shares Expires 2033-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026. F3 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 22, 2026 Filed Jun 25, 2026 00:00 UTC | Evommune, Inc. EVMN · Entity 5539 | SaleCommon Stock | 20,000 | $22.63 | $452,600.00 |
DisclosureSEC source: 0002091053-26-000005 · primarydocument.xml · nonDerivative · entry 3 Drew Janice Suzann · CIK 0002091053 · Chief of Dev. Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,794 F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 22, 2026 Filed Jun 25, 2026 00:00 UTC | Evommune, Inc. EVMN · Entity 5539 | Exercise / conversionCommon Stock | 16,161 | $2.99 | $48,321.39 |
DisclosureSEC source: 0002091053-26-000005 · primarydocument.xml · nonDerivative · entry 2 Drew Janice Suzann · CIK 0002091053 · Chief of Dev. Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026. Read SEC document |
| June 22, 2026 Filed Jun 25, 2026 00:00 UTC | Evommune, Inc. EVMN · Entity 5539 | Exercise / conversionCommon Stock | 3,839 | $3.84 | $14,741.76 |
DisclosureSEC source: 0002091053-26-000005 · primarydocument.xml · nonDerivative · entry 1 Drew Janice Suzann · CIK 0002091053 · Chief of Dev. Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 21:24 UTC | Evommune, Inc. EVMN · Entity 5539 | GrantEmployee Stock Option (Right to Buy) · Derivative | 73,892 | $0.00 Strike: $26.77 | $0.00 |
DisclosureSEC source: 0002091053-26-000003 · primarydocument.xml · derivative · entry 1 Drew Janice Suzann · CIK 0002091053 · Chief of Dev. Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,892 Underlying: Common Stock · 73,892 shares Expires 2036-04-15 F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:21 UTC | Evommune, Inc. EVMN · Entity 5539 | Tax withholdingCommon Stock | 5,074 | $17.84 | $90,520.16 |
DisclosureSEC source: 0002091053-25-000009 · primarydocument.xml · nonDerivative · entry 1 Drew Janice Suzann · CIK 0002091053 · EVP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,794 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:18 UTC | Evommune, Inc. EVMN · Entity 5539 | ConversionSeries B Preferred Stock · Derivative | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002091053-25-000007 · form4-11122025_091133.xml · derivative · entry 2 Drew Janice Suzann · CIK 0002091053 · EVP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,587 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F1 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:18 UTC | Evommune, Inc. EVMN · Entity 5539 | ConversionCommon Stock | 1,587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002091053-25-000007 · form4-11122025_091133.xml · nonDerivative · entry 1 Drew Janice Suzann · CIK 0002091053 · EVP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:15 UTC | Evommune, Inc. EVMN · Entity 5539 | GrantEmployee Stock Option (Right to Buy) · Derivative | 231,274 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0002091053-25-000005 · form4-11072025_041107.xml · derivative · entry 1 Drew Janice Suzann · CIK 0002091053 · EVP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,274 Underlying: Common Stock · 231,274 shares Expires 2035-11-04 F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on November 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.